$
Rhode Island Patient Advocacy Coalition

Cancer and Chemotherapy Side Effects

Approximately 12% of the patients in the RI Medical Marijuana Program were recommended medical marijuana by their medical practitioners for the treatment of cancer or chemotherapy.

One of the most common reasons that patients use medical marijuana is to treat negative side effects of chemotherapy, such as nausea and vomiting. As medical marjuana stimulates appetite, in addition to relieving symptoms of upset stomach, it reduces the risk for cachexia, more commonly known as wasting syndrome.


NEW RESEARCH

Harvard researcher Anju Preet, PhD presented new findings with THC at the American Association for Cancer Research. His research demonstrated that THC inhibited the growth and spread of human tumor cells from two different lung cancer cell lines.
Read more about the Harvard lung cancer study here.

From the Institute of Medicine

"In patients already experiencing sever nausea or vomiting, pills are generally ineffective because of the difficulty in swallowing or keeping a pill down, and slow onset of the drug effect. Thus an inhalation (but preferably not smoking) cannabinoid drug delivery system would be advantageous for treating chemotherapy-induced nausea."

-- Marijuana and Medicine: Assessing the Science Base, Institute of Medicine, 1999

Print a free booklet from Americans for Safe Access: Medical Marijuana and Cancer

Also visit sethgroup.org to learn about research using THC to kill brain tumor cells


Published Research

Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer. 3(10): 745-55.

McKallip, R, Lombard, C, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.

Therapeutic Uses of Cannabis. (1997) British Medical Association. Harwood Academic Pub.
"Cannabinoids are undoubtedly effective as anti-emetic agents in vomiting induced by anti-cancer drugs. Some users of both [cannabis and Marinol] find cannabis itself more effective."

Lung Cancer --

Preet et al. 2008. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 10: 339-346. <http://www.nature.com/onc/journal/v27/n3/abs/1210641a.html>

Pancreatic Cancer --

Michalski et al. 2007. Cannabinoids in pancreatic cancer: correlation with survival and pain. International Journal of Cancer (E-pub ahead of print).

Cervical Cancer --

Ramer and Hinz. 2008. Inhibition of cancer cell invasion by cannabinoids via increased cell expression of tissue inhibitor of matrix metalloproteinases-1. Journal of the National Cancer Institute 100: 59-69. <http://jnci.oxfordjournals.org/cgi/content/abstract/djm268v1>

Breast Cancer --

McAllister et al. 2007. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 6: 2921-2927. <http://mct.aacrjournals.org/cgi/content/abstract/6/11/2921>

Glioma --

Parolaro and Massi. 2008. Cannabinoids as a potential new drug therapy for the treatment of gliomas. Expert Reviews of Neurotherapeutics 8: 37-49 <http://www.future-drugs.com/doi/abs/10.1586/14737175.8.1.37>

Galanti et al. 2007. Delta9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncologica 12: 1-9. <http://www.ncbi.nlm.nih.gov/pubmed/17934890?dopt=Abstract>

Calatozzolo et al. 2007. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences 28: 304-310. <http://www.ncbi.nlm.nih.gov/pubmed/18175076?dopt=Abstract>

Sanchez, C, de Ceballos, ML. (2001) Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor. Cancer Research. (61) 5784-5789.